{
    "nctId": "NCT03481998",
    "briefTitle": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer",
    "officialTitle": "A Phase IB/II to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 104,
    "primaryOutcomeMeasure": "Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.\n2. Age: 18 - 75 years old, postmenopausal women.prepostmenopausal women, but should receive Ovary castration.\n\n   Inclusion Criteria\n3. Cohort 1 and Cohort 2 :No prior systemic anti-cancer therapy for advanced HR+ disease.\n\nCohort 3 and Cohort 4 : Patients must satisfy the following criteria for prior therapy:\n\n1. a) Progressed after 2 years during treatment of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.\n\n   b)Progressed within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.\n\n   c) Progressed while 6 month after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer if postmenopausal, or prior endocrine treatment for advanced/metastatic breast cancer if pre- or perimenopausal.\n2. One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.\n\n4. Eastern Cooperative Oncology Group \\[ECOG\\] 0-1 Measurable disease as per Response Evaluation Criterion in Solid Tumors\\[RECIST\\] 1.1\n\n5. Adequate organ and marrow function\n\nExclusion Criteria\n\n1. Confirmed diagnosis of HER2 positive disease\n2. Patients who received any endocrine therapy as neo/adjuvant therapy for breast cancer are eligible. If the neo/adjuvant therapy of any endocrine therapy , the disease-free interval must be greater than 12 months from the completion of treatment until study entry.\n3. Patients who received prior treatment with any CDK4/6 inhibitor, everolimus,fulvestant.\n4. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \\> 2), or ventricular arrhythmia which need medical intervention.\n5. Has known active central nervous system metastases.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}